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Introduction {#sec1}
============

The transforming growth factor β (TGF-β) superfamily consists of type I and II serine/threonine kinase receptors that interact with structurally related ligands, including TGF-βs and bone morphogenetic proteins (BMPs). Ligand-induced receptor complex formation results in phosphorylation of a type I receptor by a type II receptor, which, in turn, leads to phosphorylation of one of several downstream Smad proteins and signal transduction ([@bib29]).

ENG is an abundant type I transmembrane glycoprotein of the vascular endothelium that was initially recognized as a co-receptor for TGF-β1 and TGF-β3, associating with TGF-β type I and II receptors ([@bib16], [@bib20], [@bib22], [@bib48]). In most cells, the TGF-β type I receptor is activin receptor-like kinase 5 (ALK5), whereas, in endothelial cells, there is also ALK1. ENG and ALK1 were subsequently shown to bind with much higher affinity to BMP9 (also known as growth differentiation factor 2 \[GDF2\]) than to TGF-β1 and mediate its proliferation signal ([@bib13], [@bib43], [@bib51]). Post-translationally processed homodimeric BMP9 mediates signal transduction via a set of interactions involving ENG, ALK1, and a BMP type II receptor (BMPRII or ActRIIB) ([@bib9], [@bib13], [@bib17], [@bib31], [@bib51], [@bib55]). Like ALK1, ENG is essential for heart development and vascular homeostasis; *Eng*^−/−^ mice die at mid-gestation because of defective cardiovascular development and angiogenesis ([@bib12], [@bib33]). ENG is overexpressed in the vascular endothelium of solid tumors ([@bib8], [@bib41]), and functionally blocking antibodies to ENG can inhibit tumor growth via the ENG/BMP9/ALK1 pathway ([@bib32]). Mutations in the *ENG* gene cause the autosomal dominant disorder hereditary hemorrhagic telangiectasia type 1 (HHT1), a vascular dysplasia with life-threatening consequences that affects 1 in 10,000 individuals and is characterized by arteriovenous malformations, recurrent hemorrhages, and numerous sequelae ([@bib1], [@bib12], [@bib39]). Over 500 human *ENG* gene variants linked to HHT1 are currently reported in the University of Utah Department of Pathology HHT and ENG Database (<http://www.arup.utah.edu/database/ENG/ENG_welcome.php>; [@bib53]). Moreover, a circulating form of the ENG ectodomain, suggested to be released upon C-terminal cleavage of ENG by matrix metalloproteinase 14 (MMP-14) ([@bib27]), is increased at early stages of preeclampsia and serves as a predictive marker ([@bib24], [@bib57]). Despite the important role of ENG in the vascular system, its association with several diseases and potential use as a target of anti-angiogenic cancer therapy ([@bib8], [@bib45]), no high-resolution structural information is available for the protein and how it interacts with the key ligand BMP9 ([@bib14]).

ENG is predominantly expressed as an ∼180 kDa homodimer linked by intermolecular disulfide bonds ([@bib21], [@bib22]). It is composed of an N-terminal orphan region (OR), a C-terminal bipartite zona pellucida module (ZP), a single transmembrane domain, and a short cytoplasmic peptide that differs in the L and S isoforms of the protein ([Figure S1](#mmc1){ref-type="supplementary-material"}A; [@bib7], [@bib8], [@bib24], [@bib35]). Extensive attempts to crystallize the full-length ectodomain of ENG (ECTO; residues E26--G586), using different strategies to reduce N-glycan heterogeneity, were not successful. We reasoned that this may be caused by flexibility of the OR/ZP linker ([Figure S1](#mmc1){ref-type="supplementary-material"}A, arrow), which could underlie the different conformations observed by small-angle X-ray scattering ([@bib4], [@bib56]) and negative stain electron microscopy ([@bib36]). To overcome this obstacle, we combined a divide and conquer strategy with a recently developed eukaryotic expression system where proteins of interest are fused to a mammalianized version of bacterial maltose-binding protein (mMBP) ([@bib10]). Using this approach, we first elucidated the crystal structure of ENG OR, which plays a key role in signaling by binding BMP9 ([@bib14]) and does not show homology to proteins of known structure ([@bib4], [@bib36]); subsequently, we determined the structure of the OR-BMP9 complex as well as the structure of ENG ZP.

The structure of ENG OR reveals a new fold wherein a β helix-like domain with an unprecedented topology has been duplicated, followed by circular permutation. The electron density map of ENG OR in complex with BMP9 shows how the knuckle region of the ligand interacts hydrophobically with a ridge at the edge of OR, including residues previously implicated in BMP9 binding ([@bib38]). Finally, the crystal structure of ENG ZP reveals a minimal fold with the short ZP-N/ZP-C interdomain linker signature of non-polymerizing ZP modules ([@bib11]). Based on the structures of OR and ZP, a model can be presented of the ENG disulfide-bonded dimer in complex with BMP9 and the type I receptor ALK1.

Results and Discussion {#sec2}
======================

The Crystal Structure of OR Reveals Two Intertwined Domains {#sec2.1}
-----------------------------------------------------------

The structure of OR (ENG E26--S337) fused to mMBP (^M^OR; [Figures S1](#mmc1){ref-type="supplementary-material"}B and [S2](#mmc1){ref-type="supplementary-material"}A--S2C) was solved at 2.4 Å resolution by molecular replacement (MR) with MBP ([Table S1](#mmc1){ref-type="supplementary-material"}). The electron density map ([Figure S2](#mmc1){ref-type="supplementary-material"}B*)* reveals that OR is a monomer and consists of two domains that share a common new fold (OR1/OR2; [Figure 1](#fig1){ref-type="fig"}). Each domain consists of 12 β strands, which form a parallel β helix-like structure, and a single α helix. Interestingly, OR2 (β3--β14 and α1) is inserted C-terminally to OR1 β1--β2, after which OR1 (β15--β24 and α2) is completed ([Figure 1](#fig1){ref-type="fig"}B). Both domains contain a conserved disulfide bond involving C30--C207 and C53--C182, respectively ([Figures 1](#fig1){ref-type="fig"}A--1C; [Figure S2](#mmc1){ref-type="supplementary-material"}D). Two additional Cys in OR1, C242 and C330 ([Figure S1](#mmc1){ref-type="supplementary-material"}A), are likely to form a third disulfide that is not resolved because of structural disorder of residues S329--S337. However, an ^M^OR variant lacking both Cys is secreted as efficiently as wild-type ^M^OR and retains BMP9 binding activity, indicating that C242 and C330 are not crucial for folding and interaction with the ligand ([Figure S1](#mmc1){ref-type="supplementary-material"}C).Figure 1ENG OR Consists of a Duplicated and Circularly Permutated Domain(A) Cartoon representation of the OR crystal structure, consisting of two domains (OR1/OR2) and rainbow-colored from blue (N terminus) to red (C terminus). Cys residues are shown in ball-and-stick representation.(B) OR topology with OR1 and OR2 β helices colored dark and light blue, respectively. β Strands (arrows) are numbered.(C) Superposition of OR1 and OR2, colored as in (B).(D) Suggested evolution of ENG OR by gene duplication and circular permutation.(E) Superposition of ENG OR2 and tubulin cofactor C (TBCC).See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

OR Is a Result of Gene Duplication Followed by Circular Permutation {#sec2.2}
-------------------------------------------------------------------

OR1 and OR2 are only 18% identical in sequence but can be superimposed with a Cα root-mean-square deviation of 2.2 Å for 102 overlapping residues ([Figure 1](#fig1){ref-type="fig"}C; [Figure S3](#mmc1){ref-type="supplementary-material"}A). Although OR2 does not require OR1 for folding and secretion ([Figure S3](#mmc1){ref-type="supplementary-material"}B), an OR1-only construct was not secreted by itself ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Notably, the relative sequence position of the Cys moieties of the conserved disulfide is reversed in OR1 compared with OR2 so that C30 and C207 correspond to C182 and C53, respectively. Moreover, the N-terminal sequence of OR1 (including strands β1 and β2) aligns with the C-terminal part of its OR2 domain ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Taken together, these observations suggest that OR1 was generated by a duplication of an ancestral OR2 gene, followed by circular permutation ([Figure 1](#fig1){ref-type="fig"}D). Considering that ENG is only found in amniotes, a possible evolutionary relationship for OR2 may be, in turn, indicated by the fact that its structure distantly resembles tubulin cofactor C ([Figure 1](#fig1){ref-type="fig"}E). However, this β-helical molecular chaperone has a markedly different topology with a C-terminal α helix ([@bib42]).

BMP9 Binds to a Conserved Hydrophobic Groove of OR1 {#sec2.3}
---------------------------------------------------

To gain insights into how ENG modulates signaling (including cell proliferation) by interacting with ligands, we co-expressed ^M^OR and BMP9 in mammalian cells and crystallized the resulting complex ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Although the crystals only diffracted to ∼4.5 Å, the data could be phased by MR using mMBP, OR1, and an independently determined structure of BMP9 ([Figure S4](#mmc1){ref-type="supplementary-material"}B; [Table S1](#mmc1){ref-type="supplementary-material"}). In the complex crystals, the disulfide-bonded BMP9 homodimer spans two adjacent asymmetric units by lying on a symmetry axis ([Figure S4](#mmc1){ref-type="supplementary-material"}C), and the knuckle of each BMP9 molecule binds to a copy of OR1 ([Figure S4](#mmc1){ref-type="supplementary-material"}D), resulting in a "dimer of heterodimers" ([Figure 2](#fig2){ref-type="fig"}A). This arrangement is consistent with co-expression experiments of His- and Myc-tagged ^M^OR with BMP9 followed by His pull-down. Immunoblot analysis shows that Myc-^M^OR co-elutes with His-^M^OR only in the presence of BMP9, indicating that the dimeric ligand binds two copies of OR that do not interact with each other ([Figure 2](#fig2){ref-type="fig"}B). In agreement with the fact that mMBP and BMP9 are positioned on opposite sides of OR1 in the crystals ([Figure S4](#mmc1){ref-type="supplementary-material"}C), mMBP does not inhibit ENG-BMP9 binding ([Figures 2](#fig2){ref-type="fig"}A and 2B), nor does it have the ability to bind BMP9 itself ([Figure S4](#mmc1){ref-type="supplementary-material"}E, lane 11). Moreover, the OR1-BMP9 interaction is consistent with the observation that OR2---which appears to have some degree of flexibility relative to OR1 ([Figure S4](#mmc1){ref-type="supplementary-material"}F)---does not bind BMP9 when expressed by itself ([Figure S3](#mmc1){ref-type="supplementary-material"}B).Figure 2A Hydrophobic Surface of ENG OR1 Binds to the Knuckle Region of BMP9(A) Crystal structure of the OR-BMP9 complex, showing the dimer generated by crystal symmetry. OR is colored as in [Figures 1](#fig1){ref-type="fig"}B and 1C, and BMP9 chains are shown in yellow.(B) Non-reducing immunoblot and Coomassie (CBB) analysis of His pull-down of ^M^OR/BMP9 co-expression experiments. Two copies of OR bind dimeric BMP9 but do not interact with each other.(C) Detail of the OR1-BMP9 interface, with the surface of OR1 colored by hydrophobicity (orange, most hydrophobic; white, least hydrophobic).(D) Alternative view of (C), with both proteins in cartoon representation and interface residues shown in ball-and-stick representation.(E) BMP9 is pulled down by non-mMBP fused wild-type OR but not by double or triple mutant ORs, indicating that the residues shown in (D) are essential for binding.See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S8](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

The structure of the complex reveals that the ENG-BMP9 interface is largely hydrophobic ([Figure 2](#fig2){ref-type="fig"}C). It comprises OR1 residues that contribute to ENG strand β20 or immediately precede it (I271 and Q270 or N268, respectively; [Figure 2](#fig2){ref-type="fig"}D; [Figure S3](#mmc1){ref-type="supplementary-material"}A), which are close to BMP9 residues P412, T413, and Y416 ([Figure 2](#fig2){ref-type="fig"}D). Consistent with a nanomolar binding affinity for BMP9 ([Table 1](#tbl1){ref-type="table"}; [@bib4], [@bib14], [@bib24]), individual mutations of ENG residues N268, Q270, and I271 are not sufficient to disrupt the interaction between unfused OR and BMP9 ([Figure S4](#mmc1){ref-type="supplementary-material"}E, lanes 2, 4, and 5). However, double and triple combinations of these mutations show that OR1 residues Q270 and I271 ([Figure 2](#fig2){ref-type="fig"}D; [Figure S3](#mmc1){ref-type="supplementary-material"}A), which are highly conserved in mammals, are essential for BMP9 binding ([Figure 2](#fig2){ref-type="fig"}E). Importantly, neither the aforementioned individual mutations nor their combinations affect OR folding because the corresponding proteins are secreted comparably with wild-type OR ([Figure S4](#mmc1){ref-type="supplementary-material"}E, lanes 2, 4, 5, and 10; [Figure 2](#fig2){ref-type="fig"}E). Similarly, alanine mutants of D246, Y277, and F290 are secreted normally, although, in this case, the mutant proteins are still able to bind BMP9 ([Figure S4](#mmc1){ref-type="supplementary-material"}E, lanes 1, 6, and 9). In contrast, mutation of the buried hydrophobic residue M269 severely affects OR folding and secretion; however, the fraction of protein that is correctly folded and secreted retains BMP9-binding activity ([Figure S4](#mmc1){ref-type="supplementary-material"}E, lane 3). Interestingly, 9 of 11 residues located in the BMP9 β6--β7 region that contacts OR1 are conserved in BMP10, the other high-affinity ligand of ENG ([@bib14]). On the contrary, these residues differ significantly in BMPs that either do not bind ENG or interact only weakly with it ([@bib14], [@bib24]; [Figure S4](#mmc1){ref-type="supplementary-material"}G). Most importantly, the interface region of ENG also involves conserved S278 and invariant F282, whose mutation in HHT1 patients disrupts BMP9-dependent signaling ([@bib38]) as well as in vitro binding between OR and BMP9 ([Figure 2](#fig2){ref-type="fig"}E; [Figure S4](#mmc1){ref-type="supplementary-material"}E, lanes 7 and 8). Further supporting the cell signaling studies ([@bib38]) and our pull-down experiments ([Figure 2](#fig2){ref-type="fig"}E), quantitative analysis of protein-protein interaction by biolayer interferometry (BLI) shows that the mutations Q270A/I271A, S278P, and F282V completely abolish the binding of unfused OR to BMP9. Moreover, BLI confirms that mMBP fusion does not interfere with the interaction between wild-type OR and BMP9 ([Table 1](#tbl1){ref-type="table"}; [Figure S8](#mmc1){ref-type="supplementary-material"}).Table 1Kinetics Analysis of ENG-BMP9 Interaction by BLIK~D~ (M)k~on~ (M^−1^s^−1^)k~off~ (s^−1^)ECTO9.81 × 10^−9^2.0 × 10^5^ ± 1.69 × 10^3^1.98 × 10^−3^ ± 1.15 × 10^−5^OR2.95 × 10^−7^2.95 × 10^5^ ± 8.96 × 10^3^8.71 × 10^−2^ ± 9.08 × 10^−4M^OR1.79 × 10^−7^3.49 × 10^5^ ± 1.3 × 10^4^6.22 × 10^−2^ ± 7.76 × 10^−4^OR F282VNBDOR S278PNBDOR Q270A/I271ANBDmMBPNBD[^4]

Interestingly, the epitope of TRC105/SN6j, a monoclonal antibody to ENG used in clinical trials and acting as a tumor suppressor ([@bib52], [@bib8], [@bib43], [@bib45]), overlaps with the BMP9-binding region of OR1 ([Figure 2](#fig2){ref-type="fig"}A, red). This explains why TRC105, but not SN6h, whose target epitope is elsewhere on ENG ([Figure 2](#fig2){ref-type="fig"}A, cyan), inhibits BMP9-dependent signaling ([@bib43]). Similarly, overlap of the BMP9 binding site with the prodomain region of pro-BMP9 ([@bib40]) ([Figure S4](#mmc1){ref-type="supplementary-material"}H) explains why the prodomain is displaced upon interaction with ENG ([@bib31]).

The ZP Module of ENG Adopts a Minimal Fold with a Short ZP-N/ZP-C Linker {#sec2.4}
------------------------------------------------------------------------

Whereas the BMP9-binding activity of ENG depends on OR, the ZP moiety mediates its dimerization and spatial organization within the complex. Whereas an unfused ZP construct was barely secreted ([@bib10]), mMBP-fused ENG P338--G581 (^M^ZP; [Figure S1](#mmc1){ref-type="supplementary-material"}B) could be efficiently expressed as a mixture of monomer and intermolecularly disulfide-bonded homodimer ([Figure S5](#mmc1){ref-type="supplementary-material"}A, left). Although the relative ratio of the latter species significantly increased upon sample concentration ([Figure S5](#mmc1){ref-type="supplementary-material"}A, right), crystallization selected the monomer ([Figure S5](#mmc1){ref-type="supplementary-material"}B). The 2.7 Å structure of ^M^ZP displays the hallmarks of a typical ZP module composed of ZP-N and ZP-C domains with C~1~-C~4~, C~2~-C~3~ and C~5~-C~7~ disulfide connectivity, respectively ([@bib11], [@bib26], [@bib35]; [Figures 3](#fig3){ref-type="fig"}A and [4](#fig4){ref-type="fig"}A; [Figures S5](#mmc1){ref-type="supplementary-material"}C, S5D, and [S6](#mmc1){ref-type="supplementary-material"}); however, it also contains several specific features. Consistent with a role of ENG in integrin-mediated cell adhesion ([@bib22], [@bib50]), the RGD motif of the protein constitutes a short exposed loop of ZP-N ([Figure 3](#fig3){ref-type="fig"}A, left). Moreover, following the disordered OR/ZP linker residues P338--D348, C350 before αA forms a disulfide with C382 located after αBC ([Figure 3](#fig3){ref-type="fig"}A; [Figure S5](#mmc1){ref-type="supplementary-material"}D). This is reminiscent of a comparable disulfide in uromodulin (UMOD), another ZP module-containing protein ([@bib11]). In agreement with an important structural role of this disulfide, loss of C382 is associated with HHT1 ([@bib53]; University of Utah Department of Pathology HHT and ENG Database, <http://www.arup.utah.edu/database/ENG/ENG_welcome.php>), and mutation of C350 and/or C382 disrupts ENG folding and secretion ([Figures 4](#fig4){ref-type="fig"}B and 4C).Figure 3ENG Contains a Minimal ZP Module with Closely Interacting ZP-N and ZP-C Domains(A) Crystal structure of ENG ZP, colored according to secondary structure. Canonical disulfide bonds and the RGD motif are shown in ball-and-stick representation. The extra ZP-N disulfide (C350--C382) and the free ZP-C Cys involved in dimerization (C516) are also indicated.(B) Side-by-side comparison of the ENG and UMOD ZP modules. The secondary structure elements of ENG ZP-N and ZP-C are only spaced by five residues; thus, these domains are much closer to each other than the corresponding domains of UMOD, which are separated by a long linker (red). As a result, whereas the ZP-N homodimerization surface of UMOD is available to pair with another molecule (black/gray), the equivalent region of ENG interacts with ZP-C and maintains the protein in a monomeric state.See also [Figures S1](#mmc1){ref-type="supplementary-material"}, [S5](#mmc1){ref-type="supplementary-material"}, and [S6](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.Figure 4Intermolecular Disulfide Bonding of ENG ZP C516 Generates a Homodimeric Clamp for the BMP9 Ligand(A) The disulfide bonds observed in the structures of OR ([Figures 1](#fig1){ref-type="fig"}A and 1B; [Figure S2](#mmc1){ref-type="supplementary-material"}D) and ZP ([Figure 3](#fig3){ref-type="fig"}A; [Figure S5](#mmc1){ref-type="supplementary-material"}D) are indicated in red. Because neither ENG E26-S337 ([@bib14]) nor ^M^OR ([Figure 2](#fig2){ref-type="fig"}B; [Figure S1](#mmc1){ref-type="supplementary-material"}C) make intermolecular disulfide bonds, the pattern suggests that homodimerization of ENG is mediated by a C516-C516 disulfide in addition to C582-C582 ([@bib25]).(B) A non-reducing anti-His immunoblot of conditioned medium (M) shows secretion of monomeric and dimeric ENG ZP constructs (white and black arrowheads, respectively). Immunoblot of cell lysates (L) indicates that all constructs are expressed in equal amounts. Consistent with the ENG architecture proposed in (A), mutation of C516 abolishes homodimerization of ^M^ZP. Moreover, the additional C350--C382 disulfide found in ENG ZP-N ([Figure 3](#fig3){ref-type="fig"}A; [Figure S5](#mmc1){ref-type="supplementary-material"}D) is essential for ^M^ZP secretion.(C) Disulfide connectivity and secretion state of the ^M^ZP constructs analyzed in (B). Lack of secretion is symbolized by a red cross.(D) Immunoblot and Coomassie analyses of co-expression experiments under non-reducing conditions show that two ENG molecules, preferentially a disulfide-bonded dimer, bind homodimeric BMP9.(E) SEC-MALS analysis of purified His-ECTO-BMP9 complex produced in HEK293S cells reveals two conformations whose common molecular mass (red line) is consistent with a 2:2 stoichiometry.(F) Theoretical model of the complete extracellular region of homodimeric ENG in complex with BMP9. The relative orientation of the ZP-C domains cross-linked by the C516-C516 intermolecular disulfide (dashed red ellipse) is compatible with the C582-C582 disulfide ([@bib25]) at the C terminus of the ectodomain (dashed black ellipse).See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

Although the structure of ZP does not support a role for C350 in ENG dimerization ([@bib4]), Cys mutagenesis reveals that, in addition to a C582-C582 disulfide ([@bib25]), dimerization involves C516 ([Figures 4](#fig4){ref-type="fig"}A--4C). This agrees with the observation that, in the monomeric ZP structure, C516 is exposed on the surface of ZP-C ([Figure 3](#fig3){ref-type="fig"}A). By consisting of only 133 residues and containing a single intramolecular disulfide bond, the latter represents a simplified version of the ZP-C domain found in other ZP modules proteins ([@bib11], [@bib26]) ([Figure 3](#fig3){ref-type="fig"}B), including closely related betaglycan (BG)/TGF-β receptor III ([@bib8], [@bib18], [@bib34]) ([Figure S6](#mmc1){ref-type="supplementary-material"}).

In the ZP module of ENG, a minimal interdomain linker forces a 3~10~ helix within the FG loop of ZP-C to pack against the βA-βG surface of ZP-N; remarkably, the corresponding surface of UMOD mediates ZP-N/ZP-N homodimerization and is essential for protein polymerization ([@bib11]) ([Figures 3](#fig3){ref-type="fig"}A and 3B). Taken together, these observations support the idea that, in addition to the lack of a consensus cleavage site within the FG loop of ZP-C ([@bib34]), close spacing of the ZP-N and ZP-C domains of ENG and BG (which also contains a helix within its ZP-C FG loop; [Figure S6](#mmc1){ref-type="supplementary-material"}; [@bib34]) underlies their inability to polymerize like other ZP module proteins ([@bib11]) ([Figure 3](#fig3){ref-type="fig"}B).

ZP-Mediated Dimerization of ENG Clamps BMP9 within the Signaling Complex {#sec2.5}
------------------------------------------------------------------------

To investigate the solution stoichiometry of the ENG-BMP9 complex, we co-expressed His-^M^ECTO (∼120 kDa), ECTO-Myc (∼80 kDa), and BMP9 (2 × 12.1 kDa) ([Figure 4](#fig4){ref-type="fig"}D). This generates five distinct species, shown in colored boxes: His-^M^ECTO homodimer (∼240 kDa, blue), His-^M^ECTO/ECTO-Myc heterodimer (∼200 kDa, green), ECTO-Myc homodimer (∼160 kDa, red), His-^M^ECTO monomer (cyan), and ECTO-Myc monomer (magenta). His pull-down followed by anti-Myc immunoblot detects disulfide-bonded His-^M^ECTO/ECTO-Myc heterodimers bound to BMP9 ([Figure 4](#fig4){ref-type="fig"}D, lane 1). Because no monomeric ECTO-Myc is present in lane 1, BMP9 is preferentially bound by disulfide-bonded dimeric ENG. Furthermore, the same lane shows lack of homodimeric ECTO-Myc among the material pulled down by immobilized metal affinity chromatography (IMAC), excluding that BMP9 binds more than one ENG dimer or higher oligomeric forms of the protein. Analysis of a purified ECTO-BMP9 complex by size exclusion chromatography with multi-angle light scattering (SEC-MALS) confirmed these results by detecting a molecular mass of ∼150 kDa ([Figure 4](#fig4){ref-type="fig"}E).

Based on the combination of our crystallographic and biochemical data ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [4](#fig4){ref-type="fig"}A--4E), we have modeled the BMP9-bound state of homodimeric ENG ([Figure 4](#fig4){ref-type="fig"}F). As a result of the intermolecular cross-linking provided by ZP disulfide C516-C516 ([Figures 4](#fig4){ref-type="fig"}B and 4C) as well as membrane-proximal C582-C582 ([@bib25]), the two ENG molecules generate a clamp-like structure whose OR arms protrude into the extracellular space to secure the knuckles of the BMP9 homodimer. Consistent with this proposed architecture, which is compatible with MMP-14 cleavage of ENG at G586\|L587 ([@bib27]), pull-down experiments suggest that ENG ZP does not interact directly with BMP9 ([Figure S5](#mmc1){ref-type="supplementary-material"}E). However, the ZP must indirectly lower the dissociation of BMP9 from OR, because, as previously observed by surface plasmon resonance (SPR) using an OR construct truncated at P338 ([@bib4]), the dissociation rate constant (k~off~) of the OR-BMP9 complex is significantly higher than that of ECTO-BMP9 ([Table 1](#tbl1){ref-type="table"}). Together with the structure and SEC-MALS-derived stoichiometry ([Figure 4](#fig4){ref-type="fig"}E), this observation suggests that, by covalently cross-linking two protein chains ([Figure 4](#fig4){ref-type="fig"}B), ZP confers an antibody-like architecture to ENG. This has the effect of increasing the avidity of the ENG-BMP9 interaction by presenting two closely spaced OR1 binding sites that both match the homodimeric structure of the ligand and counteract its dissociation from a single OR1 site ([Figure 4](#fig4){ref-type="fig"}F). Consistent with this idea, longer OR constructs that are non-physiologically cross-linked into dimers by pairs of C350 (which normally makes an intramolecular disulfide with C382; [Figure 3](#fig3){ref-type="fig"}A; [Figure S5](#mmc1){ref-type="supplementary-material"}D) dissociate much slower from BMP9 than monomeric OR ([@bib4], [@bib14]).

Taken together, these considerations suggest that ZP not only provides a structural scaffold that spaces OR from the plasma membrane, positioning BMP9 for interaction with type I and II receptors such as ALK1 and ActRIIB, but also affects signaling by indirectly increasing ligand retention.

The ENG-BMP9 Interface Is Compatible with Binding of ALK1, but not ActRIIB, to BMP9 {#sec2.6}
-----------------------------------------------------------------------------------

BMP9-dependent signaling in endothelial cells is thought to be regulated by the association of the ligand with ENG and the type I receptor ALK1 ([@bib51]). By merging the model of ENG-BMP9 ([Figure 4](#fig4){ref-type="fig"}F) with the structure of ALK1-BMP9 in crystals of ALK1-BMP9-ActRIIB ([@bib54]), the extracellular part of an ENG-BMP9-ALK1 ternary complex can be straightforwardly modeled ([Figures 5](#fig5){ref-type="fig"}A and 5B). The resulting assembly suggests that, whereas ALK1 binds to the wrist of BMP9 ([@bib54]), the knuckle region of the ligand is recognized non-competitively by ENG OR1 ([Figures 2](#fig2){ref-type="fig"}A--2D). Also considering that ENG and ALK1 are physically spaced from each other by the finger/knuckle region of the ligand ([Figure 5](#fig5){ref-type="fig"}A), this agrees with SPR binding studies suggesting that ENG and ALK1 bind independently and non-cooperatively to BMP9 ([@bib4], [@bib14]). Accordingly, a soluble triple complex could be detected upon co-expression of BMP9, ECTO, and the extracellular part of ALK1 ([Figure 5](#fig5){ref-type="fig"}C). On the other hand, comparison of the ternary complex model ([Figure 5](#fig5){ref-type="fig"}B) with the structure of ALK1-BMP9-ActRIIB ([@bib54]; [Figure 5](#fig5){ref-type="fig"}D) indicates that OR1 and the type II receptor ActRIIB compete for the same region of BMP9. This is consistent with SPR-based evidence that ENG and ActRIIB bind to BMP9 in a mutually exclusive way ([@bib14]) and likely also applies to BMPRII because previous structural studies showed that type II receptors always interact with the knuckle region of growth factors ([@bib28]).Figure 5Theoretical Model of the ENG-BMP9-ALK1 Ternary Complex(A) Combination of the homodimeric ENG-BMP9 model shown in [Figure 4](#fig4){ref-type="fig"}F with structural information on how the type I receptor ALK1 binds BMP9 ([@bib54]) suggests a possible architecture for the co-receptor-BMP ligand-type I receptor ternary complex on the plasma membrane.(B) Top view of the ENG-BMP9-ALK1 model.(C) SDS-PAGE analysis of ENG ECTO-FLAG, ALK1-His, and BMP9 co-expression followed by His pull-down confirms that the proteins form a triple complex in solution. Consistent with the model depicted in (A) and (B), ALK1 is only able to pull down ECTO when BMP9 is present. All samples were analyzed under non-reducing conditions, except for that marked with R (reducing conditions).(D) Top view of the crystal structure of the ALK1-BMP9-ActRIIB complex ([@bib54]). Comparison with the ENG-BMP9-ALK1 model (B) suggests that ENG and ActRIIB compete for the same binding region on BMP9.

Together with the observation that ENG binds BMP9 with comparable affinity to ALK1 ([@bib4]) but is significantly more abundant than the type I receptor in endothelial cells ([@bib2], [@bib16], [@bib44], [@bib48]), these findings support a model where homodimeric BMP9 is first efficiently captured and retained on the surface of endothelial cells by the bivalent architecture of ENG, and a ternary complex is then formed upon non-competitive recruitment of ALK1 ([Figures 5](#fig5){ref-type="fig"}A--5C). Presentation of the ligand to a type II receptor, a step requiring BMP9 release from its binding site on ENG, would finally initiate signal transduction. Mirroring the case of antagonistic TGF-β family ligands ([@bib6]), this model would corroborate the idea that different receptors can compete for the same ligand to modulate signaling ([@bib37]). Although it remains to be established how captured BMP9 becomes available to ActRIIB/BMPRII, the fact that the ligand has a relatively high k~off~ for a single OR1 site ([Table 1](#tbl1){ref-type="table"}) suggests that this interaction may be triggered by transient dissociation of homodimeric BMP9 from one of its two binding sites on ENG. This would temporarily free one of the knuckle regions of BMP9 for recognition by a type II receptor located close to the ternary ENG-BMP9-ALK1 complex on the plasma membrane. Considering that ActRIIB has a lower k~off~ than OR ([Table 1](#tbl1){ref-type="table"}; [@bib4], [@bib6], [@bib54]), subsequent dissociation of the second knuckle of BMP9 from ENG would effectively result in transfer of the ALK1-bound ligand to the type II receptor. Elucidation of the details of the signal transduction mechanism will require further structural studies of the intact ternary complex. This may adopt a range of conformations not recapitulated by our crystal structure-based model as a result of flexibility at the ENG OR/ZP junction---possibly underlying the two ECTO-BMP9 states observed by SEC-MALS ([Figure 4](#fig4){ref-type="fig"}E)---as well as membrane anchoring.

Structural Basis of HHT1 {#sec2.7}
------------------------

Mapping of almost 100 gene variants linked to HHT1 ([@bib38], [@bib46], [@bib53]; University of Utah Department of Pathology HHT and ENG database, <http://www.arup.utah.edu/database/ENG/ENG_welcome.php>) onto the structure of ENG indicates that, with the exception of previously discussed OR1 residues S278 and F282 ([Figures 2](#fig2){ref-type="fig"}D and 2E), the majority of HHT1 missense mutations affect buried hydrophobic residues ([Figure S7](#mmc1){ref-type="supplementary-material"}).

Fifteen representative mutation sites, ten in OR and five in ZP, are highlighted in [Figures 6](#fig6){ref-type="fig"}A and 6B, respectively. The structure of ENG reveals that mutations L32R/H, G52D/V, L82H, V125D, L162R, L170P, L221P, I252T, L262P, I384T, and S407Q/N interfere with hydrophobic core packing, explaining the impaired expression and/or secretion of the corresponding mutants ([@bib3], [@bib38], [@bib46], [@bib47]). The same phenotype is also caused by mutations C53R, C207R, C363Y, C382W/G, C412Y/S, C493Y, and R529C, which---as observed in the case of the mutant C382S ([Figure 4](#fig4){ref-type="fig"}B)---disrupt folding by interfering with correct disulfide bond formation ([Figures S2](#mmc1){ref-type="supplementary-material"}D and [S5](#mmc1){ref-type="supplementary-material"}D; [@bib3], [@bib38], [@bib46], [@bib47]). The two effects are combined in the case of the mutation W149C, which severely impairs trafficking of ENG to the cell surface ([@bib3], [@bib47]) by replacing a largely buried hydrophobic side chain ([Figure 6](#fig6){ref-type="fig"}A) with a reactive residue that could introduce a spurious disulfide bond. Finally, ENG secretion is also affected by mutations such as D391Y and R437W ([@bib3], [@bib38]), which substitute solvent-exposed residues ([Figure 6](#fig6){ref-type="fig"}B) with hydrophobic amino acids.Figure 6HHT1-Associated Mutations Disrupt the Folding of ENG(A and B) Overview and close-ups of ENG OR (A) and ZP (B), with patient mutation sites highlighted in magenta. Disulfide bonds and C516 are shown in ball-and-stick representation; coloring is according to [Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}. Relative percentages of solvent accessibilities of residue side chains are indicated in parenthesis. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

In summary, analysis of the ENG structure suggests that most HHT1 mutations impair its folding rather than directly hinder its ability to engage in protein-protein interactions. This leads to reduced amount of functional ENG at the cell surface, thereby causing HHT1 by haploinsufficiency ([@bib46]).

Conclusions {#sec2.8}
-----------

By suggesting how the bivalent architecture of ENG secures a pool of BMP9 molecules on the plasma membrane, where they can bind to type I receptor ALK1 and become transiently available for interaction with the type II receptors ActRIIB and BMPRII, our studies shed light on some of the mechanisms underlying BMP pathway regulation. At the same time, structural knowledge of human ENG and its interaction with BMP9 constitutes a valuable framework for understanding the molecular basis of HHT. This disease is caused primarily (\>85%) by mutations in ENG (HHT1; [@bib30], [@bib39]) and ALK1 (HHT2; [@bib30], [@bib39]), but also by mutations in the common downstream signaling SMAD4 ([@bib19]) as well as in BMP9 itself in a very similar vascular anomaly syndrome ([@bib58]). Our findings also contribute to clarifying the tumor-suppressing activity of monoclonal TRC105, which targets the ENG-BMP9 interface ([@bib43]). Future studies are needed to understand how ENG forms complexes with other ligands of the TGF-β superfamily, for which it has much lower affinities than for BMP9, and to elucidate how ENG contributes to type II receptor-mediated signaling.

Experimental Procedures {#sec3}
=======================

DNA Constructs {#sec3.1}
--------------

For secreted expression of unfused proteins, cDNA fragments including tag-encoding sequences were cloned into mammalian expression vector pHLsec ([@bib5]). Except in the case of ECTO and OR constructs, which were expressed using the native signal peptide of ENG (residues M1--A25), ENG inserts were cloned in-frame with the Crypα signal peptide-encoding sequence of pHLsec. Constructs encoding non-mMBP-fused, C-terminally 8His-tagged OR1 with its native signal peptide (ENG M1-T46-(GGGS)~2~-L203-S329-C242S) and extracellular C-terminally 6His-tagged ALK1 (residues D22--G114) with its native signal peptide (residues M1--G21) were synthesized (DNA2.0/ATUM) and cloned into pHLsec. mMBP fusion proteins were expressed using pHLmMBP vectors ([@bib10]), which are available at Addgene (<https://www.addgene.org/Luca_Jovine/>). C-terminally FLAG-tagged ECTO was expressed using a previously described pCMV5 vector ([@bib23]). The cDNA encoding residues M1--R429 of human BMP9 was cloned into pHLsec without any tags so that purification of mature BMP9 depended on its ability to form a complex with His-tagged ENG partners.

Mutations were generated by overlap extension PCR, and all constructs were verified by DNA sequencing (Eurofins Genomics).

Protein Expression {#sec3.2}
------------------

Large-scale production of ^M^OR and the ^M^OR-BMP9 complex for crystallographic studies was performed in HEK293S cells expressing Endoglycosidase H (Endo H)-sensitive, high mannose-type glycoproteins ([@bib15], [@bib49]). HEK293S cells were grown in Dulbecco\'s modified Eagle\'s medium (DMEM) with 4 mM L-glutamine (Life Technologies/Thermo Fisher Scientific) and 10% (v/v) fetal bovine serum (Saveen & Werner) at 37°C, 5% CO~2~ using T flasks (150 cm^2^, BD Biosciences) or cell factories (2,528 cm^2^, Thermo Fisher Scientific). Transient transfections were essentially performed as described previously ([@bib5], [@bib10]). ^M^OR-BMP9 and ECTO-BMP9 co-transfections were performed using a 3:7 DNA mass ratio of ^M^OR versus BMP9. Because ^M^ZP does not contain N-glycosylation sites, it was expressed in HEK293T cells.

For functional assays, complexes were obtained by co-expression of His-^M^OR, Myc-^M^OR, and BMP9 in HEK293T cells using a 2.5:2.5:5 DNA ratio. His-^M^ECTO, ECTO-Myc, and BMP9 complexes were prepared using a 2:3:5 DNA ratio.

Protein Purification {#sec3.3}
--------------------

Three days post-transfection, conditioned medium containing secreted proteins was harvested, 0.22 μm-filtered (Sarstedt), and adjusted to 20 mM sodium 2-\[4-(2-hydroxyethyl)piperazin-1-yl\]ethanesulfonate (Na-HEPES) (pH 7.8), 150 mM NaCl, 5 mM imidazole (IMAC binding buffer). 10 mL nickel-nitrilotriacetic acid (Ni-NTA) agarose slurry (QIAGEN) was added per liter of medium and incubated overnight at 4°C on an overhead shaker (Heidolph). IMAC beads were then collected in a column, washed with binding buffer, and batch-eluted with a binding buffer containing 500 mM imidazole. The eluted material was concentrated using a spin filter (Millipore) with an appropriate molecular weight cutoff. Concentrated protein was subjected to SEC directly after IMAC (HEK293T-produced ^M^ZP) or after deglycosylation (HEK293S-produced ^M^OR or ^M^OR-BMP9 complex). Endo H deglycosylation of ^M^OR and ^M^OR-BMP9 was performed for 1 hr at 37°C in 120 mM sodium-potassium phosphate (pH 6.0) using a 1:10 mass ratio of enzyme to substrate. Concentrated proteins were applied to a Superdex 200 26/60 SEC column connected to an ÄKTAFPLC system (GE Healthcare). The composition of the SEC running buffer was 20 mM Na-HEPES (pH 7.8), 100 mM NaCl, and 1.5 mM D-maltose for ^M^OR; 500 mM and 200 mM NaCl were used for the ^M^OR-BMP9 complex and ^M^ZP, respectively. Protein-containing fractions were pooled, concentrated, and used for crystallization trials.

For functional assays, media were harvested from HEK293T cells transfected in 150 cm^2^ T flasks (Sarstedt). Small-scale IMAC or IMAC/SEC pull-downs were performed using the same protocol as above, linearly scaled down. Following pull-down, IMAC beads with bound ENG or ^M^ZP constructs were incubated with medium of HEK293T cells expressing BMP9 (consecutive pull-downs). Media obtained from His-^M^OR, Myc-^M^OR, and BMP9 co-expression were purified using IMAC and SEC, whereas media obtained from His-^M^ECTO, ECTO-Myc, ^M^ZP, ZP, and BMP9 co-expression or ALK1-His, ECTO-FLAG, and BMP9 co-expression were purified by IMAC. In parallel, we established that mMBP does not pull down BMP9 ([Figure S4](#mmc1){ref-type="supplementary-material"}E, lane 11).

Protein Analysis {#sec3.4}
----------------

Cell lysates were prepared by resuspending cells from a 10 cm^2^ culture well in lysis buffer (50 mM Tris-HCl/50 mM 3-(N-Morpholino)propanesulfonic acid \[MOPS\] \[pH 7.7\], 0.1% SDS, and 1 mM EDTA) supplied with protease inhibitors (Roche) and benzonase (New England Biolabs), followed by 30 min incubation at 4°C and filtration with a 0.22 μm spin filter (Millipore). Conditioned medium was centrifuged for 5 min at 500 × *g*, and the cell pellet was discarded. The supernatant was filtered using a 0.22 μm syringe filter or centrifuged at 4°C at 18,000 × *g* for 15 min.

Proteins separated by SDS-PAGE were detected with SimplyBlue SafeStain (Invitrogen/Thermo Fisher Scientific) or transferred to nitrocellulose membranes (GE Healthcare) for immunoblotting with Penta·His mouse monoclonal antibody (1:1,000, QIAGEN) or 9E10 anti-Myc mouse monoclonal antibody (1:2,000, Sigma-Aldrich). Chemiluminescence detection was performed with Western Lightning ECL Plus (PerkinElmer).

Protein-Protein Interactions {#sec3.5}
----------------------------

Experimental details for BLI measurements and SEC-MALS analysis of the ENG-BMP9 interaction are reported in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Protein Crystallization {#sec3.6}
-----------------------

Crystallization experiments were carried out by hanging drop vapor diffusion at room temperature using a mosquito crystallization robot (TTP Labtech). Droplet-shaped crystals of C-terminally 6His-tagged ^M^OR (6 mg/mL) were obtained in 0.1 M Tris-HCl (pH 8.5) and 30% (w/v) PEG1000 ([Figure S2](#mmc1){ref-type="supplementary-material"}A) and directly flash-cooled in liquid nitrogen for data collection. Because of the pH sensitivity of the ENG-BMP9 interaction, BMP9 crystals fortuitously appeared in drops set up with the ^M^OR-BMP9 complex (11 mg/mL) and a mother liquor consisting of 1.0 M LiCl, 4% (w/v) PEG6000, and 0.1 M Na-citrate (pH 3.5). For cryocooling, BMP9 crystals were adjusted to 1.0 M LiCl, 6% (w/v) PEG6000, 0.1 M Na-citrate (pH 4.0), and 30% (v/v) glycerol. Hexagonal bipyramidal crystals of N-terminally 6His-tagged ^M^OR in complex with BMP9 (^M^OR-BMP9, 6 mg/mL) grew in 1.1 M ammonium tartrate (pH 7.0) and 25% saturated sucrose ([Figure S4](#mmc1){ref-type="supplementary-material"}A). For data collection, crystals were directly flash-cooled in liquid nitrogen. Rod-shaped crystals of ^M^ZP (9 mg/mL) were obtained using 11.5% (v/v) 2-Methyl-2,4-pentanediol (MPD), 11.5% (w/v) PEG1000 and 11.5% (w/v) PEG3350, and 100 mM 2-(N-Morpholino)ethanesulfonic acid (MES)/imidazole (pH 6.5) ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Before flash-cooling in liquid nitrogen, crystals were stabilized using a 50% (v/v) precipitant mix containing 10% (v/v) glycerol.

X-Ray Diffraction Data Collection and Structure Determination {#sec3.7}
-------------------------------------------------------------

Experimental details for data collection, structure determination, as well as sequence and structure analysis are described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Data collection, refinement, and validation statistics are summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.
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